Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus adjuvant therapy in poor risk DLBCL
NCT00790036Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of everolimus in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Started Jul 2009; status: completed.
02
Drugs
everolimus
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00790036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790036.